Newsmeme!
Discover News you didn't know existed
Save the Children - Australia Hundreds of pregnant women in Zimbabwe face death because of a near-total collapse of obstetric health services, Save the Children warned today.
Shareholder-friendly stocks that have been marked to underperform the market.
Osiris Therapeutics, Inc . (NASDAQ:OSIR) announced today that it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease (GvHD), a life threatening complication of bone marrow transplantation. Prochymal is a proprietary formulation of adult mesenchymal stem cells (MSCs) designed to provide ...
COLUMBIA, Md.----Osiris Therapeutics, Inc. announced today that it has completed patient enrollment in its Phase III pivotal trial evaluating Prochymal for the treatment of steroid-refractory acute Graft versus Host Disease , a life threatening complication of bone marrow transplantation.
BERKELEY HEIGHTS, N.J.----Genta Incorporated announced today that the Company has received notice from the U.S. Food and Drug Administration that tesetaxel, the Company’s oral taxane in clinical development, has been granted designation as an “Orphan Drug” for treatment of patients with advanced melanoma.
WASHINGTON (BP)--The United States has achieved a goal ahead of schedule established by the Bush administration to provide treatment to 2 million HIV-infected people globally, the president said Dec. 1 on World AIDS Day.
CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets.
CytRx Corporation (NASDAQ: CYTR) today unveiled its corporate strategy to focus its internal resources on the clinical development of oncology drug candidates tamibarotene and INNO-206, which the Company believes offer the greatest mix of near-term and medium-term revenue potential among its clinical assets. CytRx will pursue partnerships to advance the clinical development of INNO-406 ...
(Adds details)
DUBLIN, Ireland----Research and Markets has announced the addition of the "Pipeline Insight: Orphan Diseases in Neurology - Part III: Myasthenia Gravis" report to their offering.
Related News Resources:
> HGH News
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |